Metabolic & Nutrition Research

Biochip Array Technology (BAT)


Randox’s research division offers a comprehensive range of tests directed towards Metabolic and Nutrition research. Randox's multiplex Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

Evidence Investigator, Versatile, efficient and comprehensive testing

Randox Biosciences offer a comprehensive range of technologies and solutions to make metabolic and nutrition focused research become more efficient, cost effective and accurate. These technologies, coupled with Randox’s excellent support, ensure you receive consistent results with a high level of accuracy. We produce the majority of our products in-house and are much more flexible in terms of adapting to the methods of your research project. Therefore, whatever stage of the process you are in, be it biomarker identification studies right through to clinical trials, we can provide you with a full range of arrays, biomarkers and analysers that will best fit your individual requirements.




Quality Results

• Inter and Intra-assay CV’s typically less than 10%
• Assays standardised to reference material where appropriate
• Excellent sensitivity, sub-pg/mL in many instances
• Assays validated to a clinical diagnostic standard
• Minimal batch variation, ideal for longitudinal research studies

Reduced Sample Volume
• Analyse a complete profile of biomarkers from as little as 25µl of sample
• Ideal when conservation of sample is critical

No Hidden Costs
• Full analyser package includes biochip imaging module, PC and imaging software, thermoshaker, biochip carrier handling tray and barcode scanner
• Protein arrays: all inclusive kits including reagents, biochips, buffer and multi-analyte calibrators

• Consolidation of immunoassay and molecular diagnostics onto a single platform

Metabolic Syndrome Research Arrays

What is Metabolic Syndrome?
Metabolic syndrome (MetS) is a group of cardiovascular risk factors. It is highly prevalent, with approximately 20-25% of adults affected. It is estimated that having metabolic syndrome results in a person being three times more likely to have a stroke or heart attack, and five times more likely to develop diabetes.

Underlying risk factors for MetS include: abdominal obesity, insulin resistance, physical inactivity, aging and hormonal imbalance.

The International Diabetes Foundation (IDF) has proposed the following definition for MetS

A person must have
Central obesity Increased waist circumference* (ethnicity specific)
Plus at least two of the following four factors
Raised triglycerides ≥ 150mg/dL (1.7 nmol/L)
or specific treatment for this abnormality
Reduced HDL cholesterol < 40 mg/dL (1.03 nmol/L) for men
< 50 mg/dL (1.29 nmol/L) for women
or specific treatment for this abnormality
Raised blood pressure Systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg
or treatment of previously diagnosed hypertension
Raised fasting plasma glucose Fasting plasma glucose ≥ 100 mg/dL (5.6 mmoI/L) or previously diagnosed type 2 diabetes
If above 5.6 mmoI/L or 100 mg/dL, an Oral Glucose Tolerance Test (OGTT) is strongly recommended, but not necessary, to define presence of the syndrome


The Technology explaned
Put simply, Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. It provides a unique platform for assessment of biological samples in a rapid, accurate and easy to use format.

The problem with traditional diagnosis
Traditional diagnosis takes the form of single analyte assays, even though several tests are usually required. This may result in multiple patient blood draws, increased reagent volume, ultimately increasing time to diagnosis.

The solution
In response, Randox created Biochip Array Technology and the Evidence analyser as a solution. Simultaneous detection of multiple analytes produces a complete patient profile, providing exceptional time, resource and cost savings.

The Biochip - The foundation of Biochip Array Technology
• A 9x9mm biochip acts as the solid phase and as the reaction vessel, replacing multiple cuvettes
• Biochips are pre-fabricated with an array of discrete test regions (DTRs) with a different test located at each DTR
• One biochip is used per sample to produce multiple test results simultaneously
• Randox Biochips currently hold up to 49 tests, with the potential to significantly increase this number

The biochip surface
The surface of the biochip is chemically coated using a proprietary silanation process which allows for:
• Activation of the biochip surface – ensuring uniformity and reproducibility, minimising batch to batch variations
• Modification of surface chemistry during the activation process – controlled binding of antibodies in optimal orientation

Control sites – ensuring reliable IQC Each Biochip contains internal quality control sites, which are always on the same position on every biochip. The control DTRs have set target levels in order to identify problems. If the levels for these control DTRs fall outside specified target ranges, an error code will be generated instead of a result, indicating an inaccurate result.

biochip explaned

Industry leading technology for high quality results

Save time - save costs
• Multiplex testing allows multiple tests to be carried out from a single patient sample reducing the amount of time and labour spent on individual tests

Consolidation on one system
• The world’s first platform allowing consolidation of immunoassay and molecular diagnostics with protein and DNA based biochips
• Delivering cost savings and improving laboratory efficiency

World’s most diverse test menu
• More tests available than any other sole supplier
• Routine and novel markers available

Result traceability
• Chain of custody features
• Barcoded calibrators

Complete patient profiling
• Multiplex testing with Biochip Array Technology allows clinicians and investigators to consider the complete picture allowing for well informed decisions and accurate diagnosis

Optimum laboratory efficiency
• Multi-analyte controls and calibrators available for accurate and reliable laboratory testing
• Compact benchtop system saves valuable laboratory space

Reduced sample volume
• Analyse a complete profile of biomarkers from as little as 25µl of sample
• Ideal for paediatric testing
• Saves patient distress

High throughput
• The Evidence Investigator has the ability to process 702 tests in 70 minutes using the protein arrays
• It can also detect up to 40 mutations, SNPs or pathogens in as many as 54 samples at once, in as little as three hours for molecular applications

Quality results
• Inter and intra-assay CV’s typically less than 10%
• Extensive QC capabilities with multi-analyte controls available
• User defined reference ranges
• Quantitative and qualitative results available
• Immunoassay arrays: serum, plasma, whole blood, urine, tissue, egg, feed, honey, milk, cell culture supernatant, stool, saliva, bronchoalveolar lavage fluid and forensic matrices

Ease of operation
• Straightforward testing procedure, reducing operator error
• Ready to use biochips
• Minimal sample handling

No hidden costs
• Full analyser package includes biochip imaging module, PC and imaging software, thermoshaker, biochip carrier handling tray and barcode scanner
• Protein arrays: all inclusive kits including reagents, biochips, wash buffer and multianalyte calibrators
Assay formats

Protein / Antibody assay formats
Competitive immunoassay
In a competitive immunoassay, the more analyte present in a sample, the less labelled conjugate that will bind to the immunoreaction site. Therefore the signal produced will be low. If there is little analyte in the sample, more labelled conjugate will bind to the capture antibody resulting in a higher signal.

Sandwich immunoassay
In a sandwich immunoassay, the more analyte present in a sample, the more conjugate will bind to the capture antibody. As a result, the signal will be high. Conversely, lower signal is produced when the concentration of analyte in the sample is low.

Antibody Capture
In this methodology antigens are immobilised onto the surface of the biochip and antibodies in the sample are then bound.

Highly accurate testing
• BAT has a proven high standard of accurate test results with typical CV’s ‹ 10%
• Multiplex analysis minimises analytical variation between tests

Better patient diagnosis
• Testing for multiple markers simultaneously increases the amount of patient information rapidly available to the clinician, allowing for more informed patient diagnosis

Optimum efficiency
• Multi-analyte reagents and quality control material, provides highly efficient testing while eliminating any wastage

Small sample volume
• Reduced sample volume requirements puts the patient at ease
• Patient profiling saves precious sample if further analysis is required

Cost consolidation
• Multiplex testing reduces the amount of time spent on individual tests and associated laboratory costs

Multiple sample types
• Multiple sample types can be used on one analyser including serum, plasma, whole blood, urine, oral fluid and alternative matrices
• This allows the clinician to offer flexible patient testing

Result traceability
• Barcoded controls and patient samples ensure complete traceability of results

Retrospective reporting
• Retrieve previously unreported results without additional testing, saving time

Extensive Quality Control features
• Internal quality control markers on every biochip ensure optimum assay performance
• Comprehensive Quality Control data is automatically created and displayed on LeveyJennings charts

Wide and varied test menu
• Randox’s vast biochip test menu allows clinicians to detect routine and novel markers for advanced diagnostic analysis


Research Arrays

Randox's unique Biochip Array Tecchnolgy allows the user to simultaneously measure multiple analytes from as little as 25 ul of sample. Clinically relevant markers have been grouped into specific arrays allowing researchers to profile the interactions between biomarkers within their studies.